Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products, whether the cash resources of the Company will be sufficient to fund operations as planned, including any further clinical trials of any of the Company's product candidates, and the Company's dependence on intellectual property. These factors and others affecting the Company's business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements,
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...  New product launches are critical events for the ... thought leaders about new products, Medical Affairs is one ... a new therapy performs at launch. ... leader Best Practices, LLC, critical aspects of launch support ... early stage thought leader (TL) interaction, successful TL targeting, ...
(Date:7/2/2015)... -- According to a new market research report ... Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, ... by MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 ... by 2020, at a CAGR of 11.2% during the forecast ... market data T ables and ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2
... 2011 Hamlin Memorial Hospital is planning to leverage ... of goals such as improving clinical care, meeting the ... participation in a growing Texas Regional Health Information Organization ... to improve care and at the same time meet ...
... Corporation (NASDAQ: PRXL ) will release Third Quarter ... after the close of the stock market.  The announcement will ... on the PR Newswire website at www.prnewswire.com . ... at 10:00 a.m. ET on Tuesday, May 3, 2011 to ...
Cached Medicine Technology:Hamlin Memorial Hospital Selects Prognosis ChartAccess® Comprehensive EHR 2Hamlin Memorial Hospital Selects Prognosis ChartAccess® Comprehensive EHR 3PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call 2
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, ... of technical sales expertise from the North American Board of Certified Energy Practitioners ... the most highly respected and well established national certification organization for renewable energy ...
(Date:7/3/2015)... ... 03, 2015 , ... On June 30th SEO authority and ... system called "Page One Engine" . The program, which has been hailed ... from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, publishing an ...
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon ... for the 2016 Dallas Rhinoplasty Symposium . To be held from March 4th ... will be held at the Westin Galleria Dallas. , Designed to take participants from ...
(Date:7/3/2015)... ... 2015 , ... The Erie County Bar Association Institute of ... Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law Offices. ... these types of cases. , Each year, New York State residents are hospitalized ...
(Date:7/3/2015)... ... ... Jennifer Renee Hanes, DO is the new Medical Director of its Sienna ... freestanding emergency rooms in the United States. , “We are excited to welcome Dr. ... Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. , Dr. ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... in people with diabetes than in those without the ... of Archives of Ophthalmology , one of the ... Americans had diagnosed diabetes mellitus in 2005 and another ... in the article. It is estimated that the number ...
... Oct. 13 As the first-ever report,by the United ... presented to Member States today, the Campaign to End,Fistula ... it serves.,According to its annual report, the campaign now ... in Africa, Asia and the Arab States. When it,was ...
... the Chargers Points to Myo-Med for Injury Recovery, ... Tomlinson points to Myo-Med ( http://www.myomed.com ) as,a key ... the Patriots,Tomlinson became the 17th player in NFL history ... times Sunday, a feat unexpected by critics who,thought his ...
... than Alzheimer,s patients, healthy controls , , MONDAY, Oct. 13 ... than healthy people or Alzheimer,s patients to have vitamin ... of Medicine in Atlanta. , They compared vitamin D ... 99 healthy people matched for age and other factors. ...
... N.J., Oct. 13, 2008 The AMERIGROUP Foundation,today ... for Children with,Hidden Intelligence (SCHI) to enhance the ... private school that specifically educates,multiply handicapped, underprivileged children ... is to try and alleviate the suffering of ...
... System, Supports Global Pharma Client in Closing ... CHESTER, Pa., Oct. 13 Modevity, LLC announced,today ... Imperium technology to become the primary platform for ... for their new product video content. Imperium is ...
Cached Medicine News:Health News:Vision loss more common in people with diabetes 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 3Health News:Tomlinson Attributes Rebound to Anti-Inflammatory Cream 2Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:AMERIGROUP Foundation Supports the School for Children with Hidden Intelligence 2Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: